Abstract
Background: Progressive supranuclear palsy and corticobasal syndromes (PSPS-CBS) as well as nonfluent/agrammatic primary progressive aphasia (naPPA) are often due to misfolded 4-repeat Tau, but the diversity of the associated speech disorders beyond Apraxia of Speech (AoS) is poorly understood. Objective: Investigate the full range of acoustic and lexical properties of speech to test the hypothesis that PSPS-CBS show a subset of speech impairments found in naPPA. Methods: Acoustic and lexical measures, extracted from natural, digitized semi-structured speech samples using novel, automated methods, were compared in PSPS-CBS (n=87), naPPA (n=25) and healthy controls (HC, n=41). We also explored speech in a group of PSPS-CBS patients with concomitant naPPA (PSPS-CBS+naPPA, n=8). We related these measures to grammatical performance and speech fluency, core features of naPPA, and to cerebrospinal fluid (CSF) phosphorylated tau (pTau) in patients with available biofluid. Results: Both naPPA and PSPS-CBS speech had shorter speech segments, longer pauses, higher pause rate, reduced fundamental frequency (f0) range, and slower speech rate compared to HC. naPPA speech was distinct from PSPS-CBS with shorter speech segments, more frequent pauses, slower speech rate, and reduced verb production. In both groups, acoustic duration measures generally correlated with speech fluency and grammatical performance. PSPS-CBS+naPPA resembled naPPA in most speech measures and had the narrowest f0 range. CSF pTau levels correlated with f0 range and verb production in PSPS-CBS and naPPA. Conclusion: The speech pattern of PSPS-CBS overlaps that of naPPA apart from AoS, and may be related to CSF pTau.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no conflicts of interest to report. This study was supported by grants from the National Institutes of Health (AG066597, AG017586, AG054519, NS109260, AG024904, and AG010124), Department of Defense (PR192041), Penn Institute on Aging, Alzheimer's Association (AACSF-18-567131), an anonymous donor, and the Wyncote Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants were enrolled in study protocols and participated in an informed consent procedure in accordance with the Declaration of Helsinki approved by the Institutional Review Board of the University of Pennsylvania.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access to all data anonymized for purposes of replicating procedures and results is available upon request. We share anonymized data with qualified investigators who have appropriate regulatory approval and transfer agreements.
